Company AnnouncementEPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is the first and only bispecific-based therapy approved by the FDA for ...

In June 2024, EPKINLY monotherapy was granted accelerated approval by the FDA for the treatment of R/R FL following two or more lines of systemic therapy. With the results from the confirmatory Phase ...

Incyte today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Minjuvi® ...

SHANGHAI & JERSEY CITY, N.J. Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License ...

A trial evaluated whether rituximab can attain remission in adults with frequently relapsing nephrotic syndrome (FRNS) or steroid dependent nephrotic syndrome (SDNS).

The U.S. Food and Drug Administration (FDA) has approved Epkinly (epcoritamab-bysp) plus Revlimid (lenalidomide) and Rituxan ...

This represents one of JTCC's largest and most diverse scientific contributions to ASH to date, highlighting innovations in cell therapy, targeted agents, AI-driven diagnostics, stem cell ...

AbbVie (ABBV) announced that EPKINLY, a T-cell engaging bispecific antibody administered subcutaneously, in combination with ...